News & Updates

2026-11-16

Partnering with MENDSHINE, Hotgen Biotech Accelerates In-Depth Channel Rollout of the Chinese Liver Health Project (CLHP)

2026-11-16

AHA 2026 | Sungen Biomed’s First-in-Class Anti-KCNQ1 Monoclonal Antibody SGC007 Debuts with the Preclinical Data

2026-11-16

2026 AHA Scientific Sessions: Achievement Report and Academic Exchange of SungenBiomed’s First-in-Class Myocardial-Infarction Antibody SGC001

2026-10-19

Milestone! Sungen Biomed's SGC001 Completes First Patient Enrollment and Dosing in Phase II Clinical Study for Expected Severe Acute Pancreatitis

2026-10-12

Tech Giants Rush into AI Pharma: Experimental Data and Closed-Loop Capabilities Become the Competitive Focus

2026-10-30

Great News! Yugen Pharmaceutical Advances to the National Finals of the First 2026 Biomanufacturing Competition

2026-09-24

Breaking Through the Myocardial Delivery Bottleneck: Small Nucleic Acid Technology Opens a New Era of Precision Treatment for Cardiomyopathy

2026-09-22

The AI Pharmaceutical Industry Ushers in a Window of Rapid Development

2026-09-21

Hotgen Biotech Ranks on the "2026 Beijing Top 100 Private Enterprises in Scientific and Technological Innovation" List

2026-09-18

Youngen Biotech's Next-Generation Small Nucleic Acid Therapy Showcases at BioCon China Expo 2026

2026-09-16

Youngen Biotech Showcases at the 5th BIONNOVA Beijing Innovation Forum, Exploring a New Landscape for Extrahepatic Delivery of Small Nucleic Acid Drugs

2026-09-15

Milestone | Sungen Biomed's Next-Generation Tumor Immunotherapy Backbone Drug SGT003 Completes First Subject Enrollment and Dosing